Latest Regulatory News

Patrys Limited has acquired Reliis, gaining a promising injectable formulation of quetiapine aimed at treating delirium with a rapid FDA approval pathway. This move positions Patrys at the forefront of addressing a significant unmet medical need in critical care.

5E Advanced Materials has filed a Form S-1 registration with the SEC to raise up to $30 million through a common stock offering, aiming to advance its Fort Cady boron and lithium project. The capital raise is critical as the company navigates development milestones and financial challenges.

ASX Limited has updated its FY26 expense growth guidance upwards, reflecting increased investments in risk management and technology modernisation alongside ASIC Inquiry-related costs, while reporting strong unaudited 1H26 revenue growth.

Iron Road Ltd maintained modest spending on its Central Eyre Iron Project while progressing exploration at the Mulgathing Project, with key drilling results awaited. The company also updated its strategic land options at Cape Hardy amid subdued steel market conditions.

Imricor Medical Systems has achieved multiple world-first procedures using real-time MRI guidance for cardiac ablation, advancing clinical trials and regulatory progress amid a strategic commercial expansion.

Radiopharm Theranostics has reported promising interim results from its Phase 2b trial of RAD 101, showing high concordance with MRI in brain metastases patients, while progressing multiple other clinical programs and securing a strong cash position to fund operations into 2027.

Megado Minerals is poised to advance its Iberian Copper Project with investigation permits expected early 2026, setting the stage for airborne geophysics and maiden drilling. Meanwhile, the company maintains strong positions in Canadian lithium and gold assets.

Emerald Resources NL has announced a significant update to its Dingo Range Gold Project in Western Australia, increasing its mineral resource to 1.41 million ounces of gold and securing full mining permits ahead of planned development in 2026.

Epiminder Limited has successfully listed on the ASX, raising $125 million to commercialise its FDA-approved Minder device. The company has initiated the first US implant and secured five leading medical centres for its DETECT study.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

Syrah Resources delivered a record quarter with a 34% rise in natural graphite production and advancing anode material qualification at its Vidalia facility, while navigating evolving US trade policies that could reshape its market dynamics.

GBM Resources has reported a successful Stage 1 drilling campaign at its Twin Hills gold project in Queensland, revealing significant high-grade gold mineralisation beyond existing resources. The company also advanced its portfolio strategy by divesting non-core assets and securing a substantial capital raise.